Now, nearly six years later, Jelly Roll is on track and working with nutritionist and chef Ian Larios to create healthy ...

Alcohol is responsible for a significant portion of global disease and death, contributing to 2.6 million deaths annually. It ...

Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

Mouth and throat cancers are highly treatable if caught early, but they are often diagnosed at later stages because people ...

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...